Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
H. Miles Prince(Peter MacCallum Cancer Centre), Francine M. Foss(Yale Cancer Center), Timothy M. Kuzel(Rush University), Chean Eng Ooi(Eisai (United States)), Christiane Querfeld(City of Hope), Oleg E. Akilov(University of Pittsburgh Medical Center), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Dongyuan Xing, Larisa J. Geskin(Columbia University Irving Medical Center), Preeti Singh(Indian Agricultural Statistics Research Institute), Nicholas Sauter(Eisai (United States))
Cited by 4
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610